Newer Antiplatelet Agents Epifibatide Tirofiban Etc. Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.

Slides:

Advertisements

Similar presentations

Unstable angina and NSTEMI

Advertisements

Stroke Impact It was then that it happened. To my shock and incredulity, I could not speak. That is, I could utter nothing intelligible. All that would.

Platelet Aggregation Inhibitors

MANAGEMENT OF CARDIAC SURGICAL PATIENTS RECEIVING PLATELET INHIBITORS

Update on the Medical Management of Acute Coronary Syndrome.

Oral Antiplatelet Agents: A Cornerstone of Therapy for Atherothrombotic Disease Aspirin and clopidogrel: - Reduce the risks of myocardial infarction, ischemic.

Anti-platelet drugs Dr. Ishfaq Bukhari Dec

Antiplatelet Drugs (Anti-thrombotics)

Dalia Elfawy., MD Lecturer of Anesthesia and ICU Ain Shams University 2014 RAPID REVERSAL OF ANTICOAGULATION IN TRAUMA PATIENTS.

Dr. Ishfaq Bukhari.  In healthy vasculature, circulating platelets are maintained in an inactive state by nitric oxide (NO) and prostacyclinre (PGI2)leased.

NURS 1950 Pharmacology I 1.  Objective 1: identify general reasons anticoagulants are given 2.

Coronary Artery Disease Angina Pectoris Unstable Angina Variant Angina Joseph D. Lynch, MD.

Antiplatelet Drugs - Principles Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.

Ticlopidine (Ticlid™) and Clopidogrel (Plavix™) Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.

Mosby items and derived items © 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 6 Nonopiod (Nonnarcotic) Analgesics.

Intravenous GP IIb/IIIa Inhibitors Abciximab (c7E3 Fab, ReoPro) = Human- murine chimeric monoclonal Fab antibody fragment Eptifibatide (Integrilin) =

Drugs for Coagulation disorders. There are a number of different categories of drugs which modify the coagulation process: I. Anticoagulants II. Antiplatelet.

Intracoronary Eptifibatide Bolus Administration During Percutaneous Coronary Revascularization for Acute Coronary Syndromes With Evaluation of Platelet.

BRAVO and oral GP IIb/IIIa Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center.

Dr. Mahmoud H. Taleb1 Pharmacology II Lecture 1 Pharmacology of Blood Dr. Mahmoud H. Taleb Assistant Professor of Pharmacology and Toxicology Head of Department.

TUESDAY 19TH OCTOBER2010 CATH LAB PRESENTATION. TAO /ACS study STUDY NUMBER: EFC6204 Randomized, double-blind, triple-dummy trial to compare the efficacy.

ANTIPLATELET DRUGS.

Incidence of Acute Coronary Syndromes (ACS): Statistics From Various Studies 1.4 million hospitalizations each year for ACS 944,000 hospitalizations for.

TARGET and TACTICS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for.

“Challenging practice in non-ST segment elevation Acute Coronary Syndromes (ACS)” Professor Jennifer Adgey Royal Victoria Hospital, Belfast 26th January.

Baran KW August 28, 2000 Kenneth W. Baran MD for the LIMIT AMI Investigators St. Paul Heart Clinic, St. Paul, MN, USA Sponsor: Genentech Inc., South San.

Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial Presented at AHA Scientific Sessions Nov. 15, 2000.

Antithrombotic Trialists’ Collaboration An updated collaborative overview of randomised trials of antiplatelet therapy among high-risk patients.

ANTIPLATELET DRUGS Learning objectives By the end of this lecture, students should be able to: - describe different classes of anti-platelet drugs and.

ANTIPLATELETES AGENTS BY :DR. ISRAA OMAR. The role of platelets Platelets play a critical role in thromboembolic disease like ischemic heart disease and.

ANTIPLATELETES AGENTS

Antiplatelet drugs Prof. Hanan Hagar Learning objectives By the end of this lecture, students should be able to to describe different classes of anti-platelet.

Antiplatelet drugs Dr.V.V.Gouripur. Antiplatelet drug An antiplatelet drug is a member of a class of drugs that decreases platelet aggregation and inhibits.

AGGRENOX TM Safety Head, Drug Surveillance and Information Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, Connecticut Kenneth Rakowski, MD.

Anticoagulants, Thrombolytic Agents and Antiplatelet Drugs

Agents Affecting Blood Clotting

Antiplatelet drugs Prof. Hanan Hagar Learning objectives By the end of this lecture, students should be able to To describe the role of platelets in.

Prof. Abdulrahman Almotrefi

Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: The thrombolysis in myocardial infarction risk score.

Anticoagulants Course: Pharmacology I Course Code: PHR 213 Course Instructor: Sabiha Chowdhury Lecturer Department of Pharmacy BRAC University.

The Opus Trial. Antithrombotic Therapy Stable Angina Unstable Angina ST Elevation MI Non-Q wave MI Thrombolysis Non-ST Elevation MI Q wave MI.

Bivalirudin Monotherapy Improves 30-day Clinical Outcomes in Diabetics with Acute Coronary Syndrome: Report from the ACUITY Trial Frederick Feit, Steven.

Date of download: 7/11/2016 Copyright © The American College of Cardiology. All rights reserved. From: Small molecule glycoprotein IIb/IIIa receptor inhibitors.

Drugs Used in Coagulation Disorders

Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2014 AHA/ACC Guideline for the Management of Patients.

II. Antiplatelet Drugs.

Pain treatment How drugs work on pain.

Bedside monitoring to adjust antiplatelet therapy for Coronary stenting N Engl J Med Nov 29;367: Prof. Soo-Joong Kim / R3 Yu Ho Lee.

Management of ST-Elevation Myocardial Infarction

Antithrombotic drugs Fibrinolytics

Contemporary Diagnosis and Management of Unstable Angina

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

Eptifibatide (DB00063) Approved and Investigational Drug

The following slides highlight a review of a presentation at the 16th World Congress of the World Society of Cardio-Thoracic Surgery (WSCTS) in Ottawa,

Chapter 28 Management of Patients With Coronary Vascular Disorders

ANTICOAGULANTS Dr. A. Shyam Sundar. M.Pharm., Ph.D,

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Federal University of Uberlândia, Brazil

Section D: Clinical trial update: GP IIb/IIIa inhibition

Clinical Trial Commentary

Terms and Definitions Analgesics:

Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care Marc Cohen, MD Mayo Clinic Proceedings

Prof. Abdulrahman Almotrefi

Association of Troponin Elevation with Risk of Mortality in Acute Coronary Syndromes Mortality at 42 Days  % A study by Antman and.

Antiplatelet Drugs Dr. : Asmaa Fady MD., MSC, M.B, B.Ch

Effect of Additional Temporary Glycoprotein IIb-IIIa Receptor Inhibition on Troponin Release in Elective Percutaneous Coronary Interventions After Pretreatment.

Section B: Science update

FIBRINOLYTIC DRUGS VIJAYA LECHIMI RAJ.

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

Presentation transcript:

Newer Antiplatelet Agents Epifibatide Tirofiban Etc. Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School

Epifibatide (Integrelin™) Integrelin - a cyclic peptide antagonist, has been administered to humans with positive results. Must be administered by continuous infusion 1.0 to 1.5 mg/kg/min. Short duration of action - recovery of platelet function within 2-4 hours after termination of the infusion.

Tirofiban (Aggrastat™) Development based on anti-clotting components in the venom of an African snake, the saw-scaled viper. Antiplatelet function in humans Indicated for use in patients with unstable angina and non-Q-wave myocardial infarction. Used with heparin and aspirin for treatment of acute coronary syndrome. Must be administered by continuous infusion.

DMP 728 (DuPont) Cyclic RGD analog that exhibits recognition specificity toward the GPIIb/IIIa receptor. Binds with high affinity (inhibiting adhesive proteins from binding and displacing previously bound fibrinogen from activated platelets). Effective after parenteral and oral administration.

DMP728 - a Low Molecular Weight Platelet GPIIb/IIIa Fibrinogen Receptor Antagonist Incorporating the RGD Sequence

Other Glycoprotein IIb/IIIa Antagonists in Clinical Trial Lamofiban (Ro ) [Hoffman LaRoche] Non-peptide GPIIb/IIIa receptor antagonist In clinical trial in patients with unstable angina and myocardial infarction and in patients having angioplasty. Other Orally Active GPIIb/IIIa Receptor Inhibitors in Clinical Trial (NAME). Lotrifiban (BRAVO) Lefradifiban (FROST) Orbofiban (OPUS/TIMI-16) Sibrafiban (SYMPHONY)

Essential Thrombocythemia Anagrelide (Argylin™) A life-threatening condition characterized by elevated blood platelet counts. This condition results in an abnormally high incidence of adverse events associated with thrombosis (blood clotting), including heart attack and stroke - incidence in U.S. is 7 / 100,000 individuals. ANAGRELEIDE is indicated for the treatment of essential thrombocythemia to reduce elevated platelet counts and the risk of thrombosis. Therapeutic doses do not produce significant changes in white or red cell counts and has not been shown to be leukemogenic. The drug's labeling provides guidelines for treatment of asymptomatic young adults with essential thrombocythemia. The most frequently reported adverse reactions were mild and self- limiting and included headache, palpitations, diarrhea, and abdominal pain.